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The risk of skin cancer in HIV-infected patients has not been extensively studied. 69 
Objective: 70 
To determine the risk of skin cancer in HIV-infected patients and compare it with the risk in the background 71 
population. 72 
Methods: 73 
In a matched, nationwide population-based cohort study we compared the risk of skin cancer in 4280 HIV-74 
infected patients from the Danish HIV cohort study with a background population cohort, according to the 75 
level of immunosuppression and route of transmission. 76 
Primary outcomes were time to first basal cell carcinoma (BCC), squamous cell carcinoma (SCC), or 77 
malignant melanoma (MM). 78 
Results: 79 
HIV-infected patients had an increased risk of BCC and SCC with IRRs of 1.79 (95% CI 1.43 – 2.22) and 5.40 80 
(95% CI 3.07 – 9.52), respectively, compared with the background population. We observed no increased 81 
risk of MM. Low nadir CD4 cell count was associated with an increased risk of SCC. The increased risk of BCC 82 
among HIV-infected patients was restricted to men who had sex with men. 83 
Limitations:  84 
Observational design. Small number of patients with melanoma. 85 
Conclusion: 86 
HIV-infected patients have an increased risk of BCC and SCC.. Low nadir, but not current, CD4 cell count as a 87 
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Capsule Summary: 99 
• The risk of skin cancer may be increased in HIV-infected patients. 100 
 101 
• HIV-infected patients have an increased risk of BCC and SCC. Route of infection is associated with 102 
BCC while nadir but not current CD4 cell count is associated with SCC. 103 
 104 
























Skin cancer risk is increased in immunocompromised individuals. 
1,2
 After the introduction of highly active 115 
antiretroviral therapy (HAART) the overall life expectancy for well-treated HIV-infected patients is 116 
approaching that of the background population.
3
 The immunological recovery resulting from HAART has 117 
lowered the incidence of AIDS defining cancers while there is a persistently increased risk of some non-AIDS 118 
defining cancers.
4
 Whether HIV-infected patients are at increased risk of skin cancer is not well 119 
documented partially since few countries provide reliable information on keratinocyte skin cancers (KSC), in 120 
particular basal cell carcinoma (BCC). A two-fold increased risk of BCC and squamous cell carcinoma (SCC) 121 
was demonstrated in a study of HIV-infected patients living in the US. 
5
  122 
In this study, we aim to estimate the risk of non-AIDS defining skin cancer, both KSC (comprising BCC and 123 
SCC) and MM in HIV-infected patients compared with a sex- and age matched cohort from the background 124 
population as well as siblings of these two cohorts. This unique study design using high quality population-125 
based, nationwide data enabled us to address potential confounding by skin type and family related sun 126 



















The study was carried out in accordance with The Code of Ethics of the World Medical Association 132 
(Declaration of Helsinki). We used four national registries as data sources following approval from the 133 
Danish Data Protection Agency. According to Danish law, no human participant committee approval is 134 
required for register-based studies. 135 
 136 
Setting: 137 
The Danish population consists of 5.7 million inhabitants 
6
 with an estimated adult HIV prevalence of 0.1%. 138 
HIV-infected patients are treated in eight specialized HIV centers, and followed on outpatient basis every 139 
12–24 weeks. Antiretroviral treatment is provided free of charge to all HIV-infected residents of Denmark. 140 
 141 
Data sources: 142 
We used the unique 10-digit civil registration number assigned to all individuals in Denmark 
7
 to link the 143 
data sources described below. 144 
 145 
The Danish HIV cohort study (DHCS) 146 
The DHCS is a prospective, nationwide, population-based cohort study of all HIV-infected patients aged 16 147 
years or older at time of diagnosis, treated at Danish HIV centers from 1 January 1995 with consecutive 148 
ongoing enrolment. 
8
 A detailed description of the cohort has previously been published. 
9
 Yearly updates 149 
are performed and date of first positive HIV-test and start of antiretroviral treatment (HAART) are 150 
important cohort parameters as well as route of infection, CD4 cell counts and HIV RNA measurements.  151 
 152 
The Danish Civil Registration System (DCRS) 153 
The DCRS established in 1968 stores information of vital status and demographic data on all Danish citizens. 154 
7















The Danish Cancer register (DCR) 156 
The DCR was established in 1943 and records cancer diagnoses. Cancers are classified according to 157 
modified ICD-7 diagnoses from 1943 to 1977 and ICD-10 from 1978 and up. Hospital departments 158 
(including pathology), and general practitioners report to the DCR upon first diagnosis of cancer and on 159 
change of initial cancer diagnosis. Reporting is mandatory, and the proportion of morphologically verified 160 
tumors is 89%. 
10
 From this register, we collected data on skin cancer diagnosis. 161 
 162 
Study population/inclusion and exclusion criteria 163 
All HIV-infected patients of Danish origin from the DHCS aged 16 years or more at time of diagnosis were 164 
included. For every HIV patient we randomly selected five age-and sex-matched individuals of Danish origin 165 
from the background population (“the matched background cohort”) being alive and living in Denmark at 166 
the date of inclusion. Danish origin was defined as one or both parents being born in Denmark and having 167 
Danish citizenship. This restriction by country of origin was applied to reduce potential bias by differences 168 
in skin type between HIV-infected patients and the matched background population. Date of inclusion was 169 
defined as 1 January 1995, or first date of HIV diagnosis which ever came last. We excluded patients with 170 
skin cancer prior to study enrolment.   171 
For both HIV-infected patients and the matched background cohort we included siblings in two sibling 172 
cohorts. In the DCRS, parents’ civil registration number is included for more than 99% of persons born after 173 
1952, less in persons born before. 
11
 We included siblings if they had at least one common parent, were 174 
alive and living in Denmark at time of study inclusion. 175 
 176 
Outcome 177 
The primary study outcome was time to first BCC, SCC or MM. We identified the skin cancers by the use of 178 















morphology codes; M80902, M80903, M80923, M80933 (BCC) and M80703, M80713, M80743, M80753, 180 
M80763 (SCC). SCCs and MM in other locations than the skin were not included. 181 
 182 
Statistical analysis 183 
Person-years at risk (PYR) were calculated as time from study inclusion to the date of first cutaneous 184 
cancer, death, loss to follow-up, emigration or 31 December 2014, whichever came first.  185 
Incidence rates (IR) with corresponding 95% confidence intervals (CI) were calculated for BCC, SCC and MM. 186 
By subtraction, differences in each outcome between the patient and background cohorts were calculated 187 
with corresponding 95% CI. Incidence rate ratios (IRRs) of skin cancer for HIV-infected patients compared 188 
with the matched background cohort were estimated using Poisson regression models. To address 189 
potential association with immunosuppression, we fitted a Poisson regression model for HIV-infected 190 
patients only where the following variables were considered: current CD4 cell count below 350 cells/µL 191 
(time updated variable), ever exposed to HAART (time updated variable), nadir CD4 cell count before study 192 
inclusion, sex, and age. As few patients were diagnosed with skin cancer before first treatment with HAART, 193 
in the final analysis, we only included HIV-infected patients exposed to HAART. Therefore, we were unable 194 
to address the impact of HAART. Consequently, in the final model, IRRs were estimated for current CD4 cell 195 
count (<350 versus >= 350 cells/µL), nadir CD4 cell count (per cell/µL increase), sex and age (per year 196 
increase).  197 
In order to investigate potential confounding from family related factors, in particular the level of sun 198 
exposure during childhood and skin type, we compared the risk of skin cancer between siblings of HIV-199 
infected and siblings of the matched background cohort. Further, all analyses were stratified by route of 200 
infection (men who have sex with men (MSM) versus other routes of infection), as it has been suggested 201 
that HIV-infected MSM have an increased recreational sun exposure. 
12
 The cumulative incidence function 202 



















Of the 6323 HIV-infected patients in the DHCS, we excluded 2043 (32.3%), the majority excluded due to 206 
other origin than Danish (Supplementary Figure 1). This left 4280 HIV-infected patients, who were followed 207 
for more than 41,000 PYRs. We identified 21,399 individuals for the matched background cohort, followed 208 
for more than 274,000 PYRs (Supplementary Figure 1). For descriptive data, see Table 1.  209 
 210 
Risk of BCC 211 
The IR of BCC was 2.43 (95% CI: 2.00 – 2.95)/1000 PYR) in HIV-infected patient and 1.43 (95% CI: 1.30 – 212 
1.58) /1000 PYR in the matched background cohort with a difference of 1.00 (95% CI: 0.50 – 1.49)/1000 PYR 213 
(Table 2). 214 
Figure 1 illustrates the cumulative incidence of BCC. The risk of a BCC diagnosis was increased for the HIV-215 
infected patients (IRR 1.79 (95% CI: 1.43 – 2.22)). Siblings of HIV-infected patients did not have an increased 216 
risk of BCC compared with siblings of the matched background cohort (IRR: 1.02 (95% CI: 0.75 – 1.40)). 217 
Neither current nor nadir CD4 cell count were associated with risk of BCC (Table 3). 218 
The risk of BCC differed according to route of infection. Those, who reported MSM as the route of HIV-219 
transmission had an increased risk of BCC with IRR of 2.30 (95% CI: 1.76-3.02) compared with the matched 220 
background cohort. For other routes of HIV-infection, no increased risk of BCC was observed (Table 2).  221 
 222 
Risk of SCC 223 
The IR of SCC was 0.50 (95% CI: 0.32 – 0.77)/1000 PYR) in HIV-infected patient and 0.10 (95% CI: 0.07 – 224 
0.15)/1000 PYR in the matched background cohort with a difference of 0.40 (95% CI: 0.18 – 0.62)/1000 PYR 225 
(Table 2). 226 
Figure 2 illustrates the cumulative incidence of SCC. The risk of being diagnosed with SCC was increased 227 















3.07 – 9.52) (Table 2). We did not detect any difference in risk of SCC when comparing siblings of HIV-229 
infected patients with siblings of the matched background cohort (IRR: 0.70 (95% CI: 0.09 – 5.66)). 230 
Nadir, but not current CD4 cell count was associated with a decreased risk of SCC (Table 3).  231 
The increased risk of SCC was observed in both MSM as well as HIV patients reporting heterosexual route of 232 
HIV transmission (Table 2). 233 
 234 
Risk of MM 235 
The risk of developing MM seemed not to be increased among HIV-infected patients (IRR of 0.60 (95% CI: 236 
0.28 – 1.31)) or their siblings (IRR of 0.95 (95% CI: 0.55 – 1.61)) when compared with the matched 237 
background cohort and siblings of the matched background cohort, respectively. Since all diagnoses of MM 238 
among HIV-infected patients appeared when the CD4 cell count was <350 cells/µL no further investigation 239 

















In this nationwide, population-based cohort study we observed a two-fold increased risk of BCC and a five-243 
fold increased risk of SCC in HIV-infected patients compared with the background population. The 244 
increased risk of BCC was restricted to patients reporting MSM as route of HIV-infection. There seemed to 245 
be an association between immunosuppression and SCC-risk for HIV-infected patients. The risk of MM was 246 
not increased when compared with the background population but low number of MM cases makes 247 
definitive conclusion difficult.  248 
One of the main risk factors for developing skin cancer is UV-exposure. In our study, we assumed that skin 249 
type and level of sun exposure in childhood were comparable between siblings. We found no increase in 250 
BCC-, SCC- or MM-risk among siblings of HIV-infected patients compared with siblings of the matched 251 
background cohort; hence, the data did not support confounding by sun exposure in early childhood as an 252 
explanation of the increased risk of BCC and SCC among HIV-infected patients. 253 
However, since use of sunbeds mostly happens in youth/adulthood, this might differ between siblings. 254 
Therefore, an increased risk of KSC in HIV-infected patients, but not their siblings, could be a result of either 255 
the immunosuppression caused by the HIV-infection or sunbed use in youth/adulthood. The increased risk 256 
of BCC was only seen in patients reporting MSM as route of infection. One could argue that the increased 257 
risk of BCC might be driven primarily by sun exposure in youth/adulthood not accounted for by the sibling-258 
model since previous data suggests that HIV-infected MSM might have an increased recreational UV-259 
exposure. 
12
  Further, no association between BCC and immunosuppression was observed. Difference in 260 
lifestyle habits including traveling as well as occupation might also influence the risk; however, data on 261 
these parameters were not available for this study. 262 
For SCC the picture was somewhat the opposite. SCC seemed to be associated with more severe 263 
immunosuppression as reflected by lower nadir CD4 cell count. Further, the increased SCC risk was not 264 
restricted to any route of infection. This corresponds to data from other studies in HIV-infected individuals 265 















to the level of immunosuppression. 
5,14,15
 Our results were somehow contradictory in terms of CD4 cell 267 
count with nadir, but not current CD4 cell count being associated with risk of SCC. We cannot conclude 268 
meaningfully on current CD4 cell count due to very wide CI, but it could be hypothesized that nadir CD4 269 
count is indicative of immunosuppressive history and represents a time lag between immunosuppression 270 
and skin cancer while this exposure lag is not seen with current CD4 cell counts.  271 
Human papillomavirus (HPV) alpha is associated with cervical, anogenital-and oropharyngeal cancers. HPV 272 
beta has been detected in a proportion of cutaneous SCC, and a possible etiological role has been 273 
suggested, especially in the immunosuppressed individuals. However, no mechanism of carcinogenesis has 274 
yet been found. 
16,17
  275 
A study from California found a 2.6 fold increased risk of SCC and a 2.1-increased risk of BCC when 276 
comparing HIV-positive with HIV-negative patients.
5
 The risk of BCC was almost comparable to our results, 277 
while the risk of SCC was substantially higher in our study. Numerous factors could affect rates of SCC 278 
among both HIV-infected patients and their HIV negative counterparts, which in turn will affect the 279 
estimated relative risk of SCC comparing these two groups. In the study from California, SCCs in situ were 280 
included. Further, the Californian cohort was older and had a higher CD4 cell count - the latter probably 281 
contributes substantially to the lower risk of SCC observed in the American study. Unknown and residual 282 
confounding as well as unrecognized interaction between HIV and confounders might also affect the 283 
associations found. Finally, differences in sun exposure and skin type between California and Denmark 284 
might influence the results though one would expect this to apply for both HIV-infected and controls.  285 
Our study was not designed to address the potential effect of skin cancer prevention in HIV-infected 286 
patients. In a hypothetical scenario in which prevention reduced the incidence of KSC to that of the 287 
background population, the cohort of HIV-infected patients would have to be observed for approximately 288 

















Major strengths of our study are the nationwide, population-based design with long follow-up, and the high 292 
quality and almost complete coverage of Danish registries. Furthermore, potential confounding from family 293 
related factors such as skin type and sun exposure in childhood is addressed by comparing siblings. Finally, 294 
we matched HIV-infected patients and the matched background cohort on country of origin (Denmark) 295 
reducing the potential bias introduced by differences in skin type between the two cohorts. 296 
A limitation to our study is reliance on register-based diagnoses without additional validation. A 297 
comprehensive assessment has demonstrated that the completeness and validity of the DCR is very high 298 
(95-98%). 
18
 Although including more than 4000 HIV-infected patients with long-term follow-up, we only 299 
observed small numbers of SCC and MM, limiting the power of our study and hindering more elaborate 300 
stratification. Finally, surveillance bias due to frequent consultations among HIV-infected patients might 301 
contribute to the association between KSC and HIV. However, a short-term (positive) association due to 302 
diagnostic bias alone would be followed by a later compensatory negative association (e.g., a KSC risk 303 
below one during extended follow-up), which was not found. Therefore, we do not believe that diagnostic 304 
bias alone explains our findings. 305 
 306 
Conclusion 307 
With this nation-wide, population-based cohort study, we have demonstrated that HIV-infected patients 308 
have an increased risk of BCC and SCC. Due to few events of MM solid conclusion cannot be made 309 
regarding risk of MM in HIV-infected individuals. The risk of SCC seemed to increase with increasing level of 310 
immunosuppression while the increased risk of BCC was restricted to patients reporting MSM as route of 311 

















HAART: Highly active antiretroviral therapy 315 
KSC: Keratinocyte skin cancer 316 
BCC: Basal cell carcinoma 317 
SCC: Squamous cell carcinoma 318 
MM: Malignant melanoma 319 
DHCS: The Danish HIV cohort study  320 
DCRS: The Danish Civil Registration System  321 
DCR: The Danish Cancer register  322 
PYR: Person-years at risk  323 
IR: Incidence rate 324 
CI: Confidence interval 325 
IRR: Incidence rate ratios  326 
MSM: Men who have sex with men 327 





















References  335 
1 Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681–336 
91. 337 
2 Omland SH, Gniadecki R, Hædersdal M, Helweg-Larsen J, Omland LH. Skin Cancer Risk in Hematopoietic 338 
Stem-Cell Transplant Recipients Compared With Background Population and Renal Transplant 339 
Recipients: A Population-Based Cohort Study. JAMA Dermatol 2016; 152: 177–83. 340 
3 Lohse N, Hansen A-BE, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 341 
1995-2005. Ann Intern Med 2007; 146: 87–95. 342 
4 Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in 343 
the United States. Int J Cancer 2008; 123: 187–94. 344 
5 Silverberg MJ, Leyden W, Warton EM, Quesenberry CP, Engels EA, Asgari MM. HIV infection status, 345 
immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst 2013; 105: 350–346 
60. 347 
6 Folketal - Danmarks Statistik. https://www.dst.dk/da/Statistik/emner/befolkning-og-valg/befolkning-og-348 
befolkningsfremskrivning/folketal (accessed March 9, 2018). 349 
7 Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur 350 
J Epidemiol 2014; 29: 541–9. 351 
8 Lohse N, Hansen A-BE, Jensen-Fangel S, et al. Demographics of HIV-1 infection in Denmark: results from 352 
the Danish HIV Cohort Study. Scand J Infect Dis 2005; 37: 338–43. 353 
9 Omland LH, Ahlström MG, Obel N. Cohort profile update: the Danish HIV Cohort Study (DHCS). Int J 354 
Epidemiol 2014; 43: 1769–1769e. 355 
10 Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011; 39: 42–5. 356 
11 Christensen K, Schmidt MM, Vaeth M, Olsen J. Absence of an environmental effect on the recurrence of 357 
facial-cleft defects. N Engl J Med 1995; 333: 161–4. 358 















13 Jepsen P, Vilstrup H, Andersen PK. The clinical course of cirrhosis: The importance of multistate models 360 
and competing risks analysis. Hepatol Baltim Md 2015; 62: 292–302. 361 
14 Jensen P, Hansen S, Møller B, et al. Skin cancer in kidney and heart transplant recipients and different 362 
long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40: 177–86. 363 
15 Gjersvik P, Hansen S, Møller B, et al. Are heart transplant recipients more likely to develop skin cancer 364 
than kidney transplant recipients? Transpl Int Off J Eur Soc Organ Transplant 2000; 13 Suppl 1: S380-381. 365 
16 Arron ST, Ruby JG, Dybbro E, Ganem D, Derisi JL. Transcriptome sequencing demonstrates that human 366 
papillomavirus is not active in cutaneous squamous cell carcinoma. J Invest Dermatol 2011; 131: 1745–367 
53. 368 
17 Howley PM, Pfister HJ. Beta genus papillomaviruses and skin cancer. Virology 2015; 479–480: 290–6. 369 
18 Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry--history, content, quality 370 
and use. Dan Med Bull 1997; 44: 535–9. 371 
 372 















Figure legends 374 
Figure 1: The cumulative incidence of basal cell carcinoma (BCC) among HIV-infected patients compared 375 
with the matched background population. 376 
Figure 2: The cumulative incidence of squamous cell carcinoma (SCC) among HIV-infected patients 377 



























n = 5647 
Siblings of the 
background cohort, 
n = 26.875 
Males, n (%) 3641 (85.1) 18.204 (85.1) 3020 (53.5) 14.137 (52.5) 
Age at study inclusion, median (IQR) 38.6 (31.7-46.8) 38.6 (31.7-46.8) 34.2 (29.3 – 39.7) 34.5 (29.7 – 39.7) 
Route of infection, n (%) 
   MSM 
   Heterosexually 
   Intravenous drug use 





















CD4 cell count at study inclusion 
(cells/µL), median (IQR) 
300 (120-504) n.a. n.a. n.a. 

















Table 2. Risk of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) among HIV-infected patients of Danish origin compared with the 
matched background population. 
 
   BCC   SCC   MM  
Route of 
infection 
  n Rate per 1000 PYR 
(95% CI) 
IRR (95% CI) * n Rate per 1000 PYR 
(95% CI) 
IRR (95% CI) * n Rate per 1000 PYR 
(95% CI) 
IRR (95% CI) * 
All HIV-infected patients 101 2.43 (2.00 – 2.95) 1.79 (1.44 – 2.22) 21 0.50 (0.32 – 0.77) 5.40 (3.07 – 9.52) 7 0.17 (0.08 – 0.35) 0.60 (0.28 – 1.31) 
 Matched background cohort 392 1.43 (1.30 - 1.58) Ref. 28 0.10 (0.07 - 0.15) Ref. 79 0.29 (0.23 – 0.36) Ref. 
      MSM HIV-infected patients 70 3.06 (2.42 – 3.87) 2.30 (1.76 – 3.02) 12 0.52 (0.30 – 0.92) 4.30 (2.10 – 8.82) 4 0.17 (0.07 – 0.47) 0.60 (0.21 – 1.66) 
 Matched background cohort 208 1.42 (1.24 – 1.62) Ref. 20 0.14 (0.09 – 0.21) Ref. 45 0.31 (0.23 – 0.41) Ref. 
      Other HIV-infected patients 31 1.66 (1.17 – 2.36) 1.18 (0.81 – 1.73) 9 0.48 (0.25 – 0.93) 8.09 (3.12 – 21.00) 3 0.16 (0.05 – 0.50) 0.61 (0.19 – 1.98) 
 Matched background cohort 184 1.44 (1.25 – 1.67) Ref. 8 0.06 (0.03 – 0.13) Ref. 34 0.27 (0.19 – 0.37) Ref. 
* adjusted for age and sex. Abbreviations: BCC: Basal cell carcinoma, PYR: person years of observation, IRR: incidence rate ratio, CI: confidence 
















Table 3. Risk of BCC and SCC among HIV-infected patients of Danish origin according to current CD4 cell count, nadir CD4 cell count, sex and age. 
 IRR (95% CI) for BCC IRR (95% CI) for SCC 
CD4 cell count <350 0.55 (0.28-1.07) 1.12 (0.36-3.46) 
CD4nadir (per cell/µL increase) 0.999 (0.998-1.009) 0.994 (0.990-0.999) 
Sex 2.12 (0.77-5.87) 2.04 (0.27-15.68) 
Age (per year increase) 1.07 (1.05-1.10) 1.12 (1.07-1.18) 
Abbreviations: IRR: incidence rate ratio, CI: confidence interval  
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